/
Other
Tics
106
Pipeline Programs↗
110
Active Trials↗
389
Companies Involved↗
Tics is a highly competitive landscape with 106 programs across 389 companies. The most active players are Haisco Pharmaceutical Group Co., Ltd., AstraZeneca, Qilu Pharmaceutical Co., Ltd.. 3 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical18
Phase 176
Phase 29
Phase 33
Approved
No programs
Analysis
Modality Breakdown
98%
Small molecule
99 of 101 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 101 classified programs, each share of the total. Modality classified for 100% of 106 pipeline programs.
Analysis
Trial Status
2,299
clinical trials
Completed1,940 · 84%
Unknown status121 · 5%
Terminated90 · 4%
Recruiting60 · 3%
Withdrawn36 · 2%
Not yet recruiting26 · 1%
Other26 · 1%
Clinical Trials
Trial Activity
2299 trials
Page 1 of 154
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)